<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04644796</url>
  </required_header>
  <id_info>
    <org_study_id>2037544</org_study_id>
    <nct_id>NCT04644796</nct_id>
  </id_info>
  <brief_title>A Randomized Trial of Exparel vs Saline in Opioid Reduction of Pain Management Following Lumbar Spine Surgeries.</brief_title>
  <acronym>Exparel</acronym>
  <official_title>A Randomized Controlled Trial of the Effect of Liposomal Bupivacaine (Exparel) When Compared to Saline Control in Reducing Opioid Utilization for Pain Management in Postoperative Lumbar Spine Surgeries.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Missouri-Columbia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Missouri-Columbia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish a relationship between liposomal bupivacaine&#xD;
      surgical site injection and postop opioid utilization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multiple studies have shown that people who are taking opioids for acute pain have a greater&#xD;
      likelihood of long-term opioid use. Many efforts have been made to reduce postop pain and&#xD;
      opioid use, including developments in incisional site injections of local anesthetics,&#xD;
      continuous incisional site anesthetic pain pumps, as well as multimodal comprehensive pain&#xD;
      management, yet patients undergoing lumbar spine surgeries continue to depend on opioids for&#xD;
      relief. Liposomal bupivacaine (LB) (Exparel) is a novel formulation of long-acting&#xD;
      bupivacaine, lasting for up to 72 hours following injection. LB has been shown to be&#xD;
      efficacious in reducing postop pain and opioid utilization in several different surgical&#xD;
      settings, however its utility in spine surgeries has still yet to be established. The goal of&#xD;
      this study is to determine the efficacy of liposomal bupivacaine vs saline in lumbar spine&#xD;
      surgeries in reducing opioid utilization as well as determine if there difference patient&#xD;
      reported outcomes and length of hospital stay.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 10, 2021</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomly assigned to either the treatment group or the placebo group. Patients in the study group will receive liposomal bupivacaine at the end of the procedure (following fascial closure, but prior to superficial closure), while patients in the placebo group will receive sterile saline. The injectate should be injected slowly and deeply, infusing ~1-2 mL according to manufacture guidelines for infiltration. According to these guidelines, injection should utilize a moving needle technique (inject while withdrawing the needle) at multiple locations surrounding the incision(s) to achieve maximal effect. Care will be taken to aspirate prior to injection to minimize the risk of intravascular injection of medication.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Liposomal bupivacaine can be differentiated visually from normal saline. In order to blind the surgeons from treatment vs control, the syringes containing the medication or saline will be sheathed by the investigational drug study department.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative Opioid Utilization</measure>
    <time_frame>Until final follow-up, up to 8 weeks.</time_frame>
    <description>Comparing post operative opioid utilization between treatment and placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post Operative Pain Scores</measure>
    <time_frame>Until final follow-up, up to 8 weeks.</time_frame>
    <description>Comparing post operative pain scores between treatment and placebo group. Using Visual Analogue Scale (VAS) pain score with scale 0 to 10 with 0 being no pain and 10 being the worst pain of your life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay</measure>
    <time_frame>Until final follow-up, up to 8 weeks.</time_frame>
    <description>Determining how long patient is in hospital.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative Data and Complications</measure>
    <time_frame>Until final follow-up, up to 8 weeks.</time_frame>
    <description>Comparing time in operating room, time in postanesthesia care unit, intraoperative complications, acute postoperative complication, opioid complications, cost of local infiltrates will be collected from patient charts.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Lumbar Spine Degeneration</condition>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients in this group will be given the placebo (sterile saline).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients in this group will be given the study drug (liposomal bupivacaine).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>saline 0.9%</intervention_name>
    <description>Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>sterile saline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal bupivacaine</intervention_name>
    <description>Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.</description>
    <arm_group_label>Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing isolated lumbar spine procedures using a posterior approach.&#xD;
&#xD;
          -  Surgical spine procedures include:&#xD;
&#xD;
          -  Single-level lumbar spine surgeries with or without fusion&#xD;
&#xD;
          -  Multi-level lumbar spine surgeries with or without fusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Procedures involving intrathecal space&#xD;
&#xD;
          -  Patients with documented allergy to local anesthetics (bupivacaine, lidocaine,&#xD;
             procaine, benzocaine).&#xD;
&#xD;
          -  Acute lumbar trauma that requires immediate spine stabilization&#xD;
&#xD;
          -  Revision of failed back surgeries (including nonunion and malunion)&#xD;
&#xD;
          -  Revision of wound or hardware&#xD;
&#xD;
          -  Contraindication to regional anesthesia&#xD;
&#xD;
          -  Patients with chronic use of opioid medications&#xD;
&#xD;
          -  Liver dysfunction (INR &gt; 1.5, albumin &lt;2.8g/dl, bilirubin &gt;2mg/dl)&#xD;
&#xD;
          -  Renal dysfunction (eGFR &lt; 60ml/min/1.73m2)&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease requiring continuous oxygen&#xD;
             supplementation&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fassil Mesfin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Missouri - Missouri Orthopaedic Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stacee Baker, BSN, RN</last_name>
    <phone>(573) 884-9017</phone>
    <email>bakersa@health.missouri.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Fassil Mesfin, MD, PhD</last_name>
    <phone>(573) 882-2663</phone>
    <email>mesfinf@health.missouri.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Missouri Orthopaedic Institute</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michaela R Thomson, BS</last_name>
      <phone>573-884-1128</phone>
      <email>mrtmb2@health.missouri.edu</email>
    </contact>
    <contact_backup>
      <last_name>Abigail York, BS</last_name>
      <phone>(660) 734-4056</phone>
      <email>yorkaa@health.missouri.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/drugoverdose/epidemic/index.html</url>
    <description>Drug Overdose Epidemic Data</description>
  </link>
  <link>
    <url>https://www.exparel.com/hcp/about-exparel/dosing-and-administration</url>
    <description>Exparel dosage guidelines</description>
  </link>
  <results_reference>
    <citation>Butz DR, Shenaq DS, Rundell VL, Kepler B, Liederbach E, Thiel J, Pesce C, Murphy GS, Sisco M, Howard MA. Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-Based Breast Reconstruction. Plast Reconstr Surg Glob Open. 2015 Jun 5;3(5):e391. doi: 10.1097/GOX.0000000000000355. eCollection 2015 May.</citation>
    <PMID>26090281</PMID>
  </results_reference>
  <results_reference>
    <citation>Reynolds RA, Legakis JE, Tweedie J, Chung Y, Ren EJ, Bevier PA, Thomas RL, Thomas ST. Postoperative pain management after spinal fusion surgery: an analysis of the efficacy of continuous infusion of local anesthetics. Global Spine J. 2013 Mar;3(1):7-14. doi: 10.1055/s-0033-1337119. Epub 2013 Mar 2.</citation>
    <PMID>24436846</PMID>
  </results_reference>
  <results_reference>
    <citation>Grant GJ, Barenholz Y, Bolotin EM, Bansinath M, Turndorf H, Piskoun B, Davidson EM. A novel liposomal bupivacaine formulation to produce ultralong-acting analgesia. Anesthesiology. 2004 Jul;101(1):133-7.</citation>
    <PMID>15220782</PMID>
  </results_reference>
  <results_reference>
    <citation>Surdam JW, Licini DJ, Baynes NT, Arce BR. The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. J Arthroplasty. 2015 Feb;30(2):325-9. doi: 10.1016/j.arth.2014.09.004. Epub 2014 Sep 16.</citation>
    <PMID>25282071</PMID>
  </results_reference>
  <results_reference>
    <citation>American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain management in the perioperative setting: an updated report by the American Society of Anesthesiologists Task Force on Acute Pain Management. Anesthesiology. 2012 Feb;116(2):248-73. doi: 10.1097/ALN.0b013e31823c1030.</citation>
    <PMID>22227789</PMID>
  </results_reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 25, 2020</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Missouri-Columbia</investigator_affiliation>
    <investigator_full_name>Fassil Mesfin</investigator_full_name>
    <investigator_title>Assistant Professor of Neurological Surgery, Director of Complex Spine and Spine Oncology Assistant, Director for Neurological Surgery Residency Program</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

